FAIR VALUE DISCLOSURES (Details Textual) - USD ($) $ in Thousands	1 Months Ended			9 Months Ended
	Apr. 30, 2016	Jan. 31, 2016	Aug. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate				15.00%
Payments to Acquire Intangible Assets				$ 144,494	$ 30,500
Long-term Debt, Total				118,807		$ 113,427
Finite-Lived Intangible Assets, Gross				214,892		76,498
Inventory, Finished Goods, Gross				12,083		1,897
Accrued Royalties Related To Asset Purchase				3,882	$ 0
Cranford Pharmaceuticals [Member] | Non Compete Agreement [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate	10.00%
Finite-Lived Intangible Assets, Gross	$ 600
Finite-Lived Intangible Asset, Useful Life	7 years
Cranford Pharmaceuticals [Member] | Prepaid Purchase Order [Member]
Fair Value Inputs, Assets, Quantitative Information
Prepaid Expense and Other Assets, Current	$ 300
Merck Sharp Dohme B.V [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate		10.00%
Finite-Lived Intangible Assets, Gross		$ 75,000
Finite-Lived Intangible Asset, Useful Life		10 years
Acquisition Costs Capitalized		$ 300
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information
Notes Payable, Fair Value Disclosure				176,600
New Drug Applications [Member] | Cranford Pharmaceuticals [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate	12.00%
Payments to Acquire Intangible Assets	$ 60,000
Finite-Lived Intangible Assets, Gross	$ 52,400
Finite-Lived Intangible Asset, Useful Life	10 years
Acquisition Costs Capitalized	$ 300
Inventory, Finished Goods, Gross	10,900
Funds Held In Escrow In Relation To Asset Purchase	5,000
Accrued Royalties Related To Asset Purchase	3,900
Asset Acquisition Purchase Price	$ 64,200
Marketing and Distribution Rights [Member]
Fair Value Inputs, Assets, Quantitative Information
Finite-Lived Intangible Assets, Gross			$ 1,000	$ 11,042		$ 1,000
Finite-Lived Intangible Asset, Useful Life			7 years	4 years 8 months 12 days
Marketing and Distribution Rights [Member] | H2 - Pharma, LLC [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate		10.00%
Payments to Acquire Intangible Assets		$ 8,800
Finite-Lived Intangible Assets, Gross		$ 10,000
Finite-Lived Intangible Asset, Useful Life		4 years
Acquisition Costs Capitalized		$ 42
Accrued Royalties Assumed in Asset Purchase		$ 1,200